AG˹ٷ

STOCK TITAN

[Form 4] VolitionRX Limited Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

VolitionRx Ltd. (VNRX) � Form 4 filing

On 08/05/2025, President, CEO & Director Cameron John Reynolds purchased 78,125 shares of common stock at $0.64 per share during the company’s registered direct offering (transaction code “P�). The acquisition raises his direct holdings to 2,609,847 shares. Reynolds also controls 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse, bringing his total beneficial ownership to roughly 3.65 million shares. No derivative securities were exercised or sold, and no dispositions were reported.

This insider buy represents an out-of-pocket investment of approximately $50,000, strengthening management’s alignment with shareholders. The shares were obtained via a primary issuance, indicating additional capital raised by the company.

VolitionRx Ltd. (VNRX) � Comunicazione Modulo 4

Il 08/05/2025, il Presidente, CEO e Direttore Cameron John Reynolds ha acquistato 78.125 azioni ordinarie al prezzo di 0,64 $ per azione durante l'offerta diretta registrata della società (codice transazione “P�). L'acquisizione porta le sue partecipazioni dirette a 2.609.847 azioni. Reynolds detiene inoltre il controllo di 1.007.718 azioni tramite Concord International, Inc. e 34.076 azioni possedute da suo coniuge, portando la sua proprietà totale beneficiaria a circa 3,65 milioni di azioni. Non sono stati esercitati o venduti titoli derivati e non sono state segnalate cessioni.

Questo acquisto da parte dell'insider rappresenta un investimento diretto di circa 50.000 $, rafforzando l'allineamento della direzione con gli azionisti. Le azioni sono state ottenute tramite un'emissione primaria, indicando un aumento di capitale aggiuntivo per la società.

VolitionRx Ltd. (VNRX) � Presentación del Formulario 4

El 08/05/2025, el Presidente, CEO y Director Cameron John Reynolds dzó 78,125 acciones comunes a $0.64 por acción durante la oferta directa registrada de la empresa (código de transacción “P�). La adquisición eleva su participación directa a 2,609,847 acciones. Reynolds también controla 1,007,718 acciones a través de Concord International, Inc. y 34,076 acciones en poder de su cónyuge, sumando una propiedad beneficiaria total de aproximadamente 3.65 millones de acciones. No se ejercieron ni vendieron valores derivados, y no se reportaron disposiciones.

Esta compra por parte del insider representa una inversión directa de aproximadamente $50,000, fortaleciendo la alineación de la dirección con los accionistas. Las acciones se obtuvieron mediante una emisión primaria, lo que indica capital adicional recaudado por la empresa.

VolitionRx Ltd. (VNRX) � Form 4 제출

2025� 5� 8�, 사장 � CEO � 이사� Cameron John Reynolds가 회사� 등록 직Ϊ 공모(거래 코드 “P�)에서 주당 $0.6478,125 보통주를 매수했습니다. 이번 취득으로 그의 직Ϊ 보유 주식은 2,609,847주가 되었습니�. Reynolds� 또한 Concord International, Inc.� 통해 1,007,718주를 통제하고 있으�, 배우자가 보유� 34,076주를 포함� � 실질 소유 주식은 � 365�주에 이릅니다. 파생 증권은 행사하거� 매도하지 않았�, 처분� 보고되지 않았습니�.

이번 내부� 매수� � $50,000� 직Ϊ 투자�, 경영진과 주주 간의 이해관� 일치� 강화합니�. 주식은 1� 발행� 통해 취득되었으며, 이는 회사가 추가 자본� 조달했음� 의미합니�.

VolitionRx Ltd. (VNRX) � Dépôt du Formulaire 4

Le 08/05/2025, le Président, PDG et Directeur Cameron John Reynolds a acheté 78 125 actions ordinaires à 0,64 $ par action lors de l'offre directe enregistrée de la société (code de transaction « P »). Cette acquisition porte ses participations directes à 2 609 847 actions. Reynolds contrôle également 1 007 718 actions via Concord International, Inc. et 34 076 actions détenues par son conjoint, portant sa propriété bénéficiaire totale à environ 3,65 millions d'actions. Aucun titre dérivé n'a été exercé ou vendu, et aucune cession n'a été signalée.

Cet achat d'initié représente un investissement personnel d'environ 50 000 $, renforçant l'alignement de la direction avec les actionnaires. Les actions ont été obtenues par une émission primaire, indiquant un capital supplémentaire levé par la société.

VolitionRx Ltd. (VNRX) � Form 4 Meldung

Am 08.05.2025 erwarb der Präsident, CEO und Direktor Cameron John Reynolds während des registrierten Direktangebots des Unternehmens (Transaktionscode „P�) 78.125 Stammaktien zu je 0,64 $. Durch den Erwerb erhöht sich sein direkter Aktienbestand auf 2.609.847 Aktien. Reynolds kontrolliert außerdem 1.007.718 Aktien über Concord International, Inc. sowie 34.076 Aktien, die von seiner Ehefrau gehalten werden, was seine gesamte wirtschaftliche Beteiligung auf etwa 3,65 Millionen Aktien bringt. Es wurden keine Derivate ausgeübt oder verkauft und keine Veräußerungen gemeldet.

Dieser Insider-Kauf stellt eine Barinvestition von etwa 50.000 $ dar und stärkt die Übereinstimmung der Geschäftsführung mit den Aktionären. Die Aktien wurden durch eine Primärausgabe erworben, was auf eine zusätzliche Kapitalaufnahme des Unternehmens hinweist.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: CEO invests ~$50k, lifts direct stake to 2.6 M shares; positive insider signal.

The purchase at $0.64 during a registered direct offering shows the CEO committing fresh capital at the same terms as outside investors. Direct ownership grows by 3.1%, while total beneficial control now approaches 3.65 M shares. Insider buying—especially from the chief executive—is often interpreted as confidence in future prospects and can improve market sentiment. No sales or derivative conversions accompany this filing, underscoring a purely additive transaction. Given the modest size relative to float but clear optical value, I view the disclosure as incrementally positive.

TL;DR: New equity issuance dilutes existing holders; overall impact neutral.

While insider participation is welcome, the shares were issued through a registered direct offering, which increases outstanding share count. Unless proceeds are deployed effectively, dilution may offset the benefit of insider confidence. The transaction size�78,125 shares—is small in isolation and unlikely to materially alter control dynamics. Absence of a Rule 10b5-1 plan box suggests a discretionary purchase. Net effect is neutral: positive governance signal balanced by dilution risk.

VolitionRx Ltd. (VNRX) � Comunicazione Modulo 4

Il 08/05/2025, il Presidente, CEO e Direttore Cameron John Reynolds ha acquistato 78.125 azioni ordinarie al prezzo di 0,64 $ per azione durante l'offerta diretta registrata della società (codice transazione “P�). L'acquisizione porta le sue partecipazioni dirette a 2.609.847 azioni. Reynolds detiene inoltre il controllo di 1.007.718 azioni tramite Concord International, Inc. e 34.076 azioni possedute da suo coniuge, portando la sua proprietà totale beneficiaria a circa 3,65 milioni di azioni. Non sono stati esercitati o venduti titoli derivati e non sono state segnalate cessioni.

Questo acquisto da parte dell'insider rappresenta un investimento diretto di circa 50.000 $, rafforzando l'allineamento della direzione con gli azionisti. Le azioni sono state ottenute tramite un'emissione primaria, indicando un aumento di capitale aggiuntivo per la società.

VolitionRx Ltd. (VNRX) � Presentación del Formulario 4

El 08/05/2025, el Presidente, CEO y Director Cameron John Reynolds dzó 78,125 acciones comunes a $0.64 por acción durante la oferta directa registrada de la empresa (código de transacción “P�). La adquisición eleva su participación directa a 2,609,847 acciones. Reynolds también controla 1,007,718 acciones a través de Concord International, Inc. y 34,076 acciones en poder de su cónyuge, sumando una propiedad beneficiaria total de aproximadamente 3.65 millones de acciones. No se ejercieron ni vendieron valores derivados, y no se reportaron disposiciones.

Esta compra por parte del insider representa una inversión directa de aproximadamente $50,000, fortaleciendo la alineación de la dirección con los accionistas. Las acciones se obtuvieron mediante una emisión primaria, lo que indica capital adicional recaudado por la empresa.

VolitionRx Ltd. (VNRX) � Form 4 제출

2025� 5� 8�, 사장 � CEO � 이사� Cameron John Reynolds가 회사� 등록 직Ϊ 공모(거래 코드 “P�)에서 주당 $0.6478,125 보통주를 매수했습니다. 이번 취득으로 그의 직Ϊ 보유 주식은 2,609,847주가 되었습니�. Reynolds� 또한 Concord International, Inc.� 통해 1,007,718주를 통제하고 있으�, 배우자가 보유� 34,076주를 포함� � 실질 소유 주식은 � 365�주에 이릅니다. 파생 증권은 행사하거� 매도하지 않았�, 처분� 보고되지 않았습니�.

이번 내부� 매수� � $50,000� 직Ϊ 투자�, 경영진과 주주 간의 이해관� 일치� 강화합니�. 주식은 1� 발행� 통해 취득되었으며, 이는 회사가 추가 자본� 조달했음� 의미합니�.

VolitionRx Ltd. (VNRX) � Dépôt du Formulaire 4

Le 08/05/2025, le Président, PDG et Directeur Cameron John Reynolds a acheté 78 125 actions ordinaires à 0,64 $ par action lors de l'offre directe enregistrée de la société (code de transaction « P »). Cette acquisition porte ses participations directes à 2 609 847 actions. Reynolds contrôle également 1 007 718 actions via Concord International, Inc. et 34 076 actions détenues par son conjoint, portant sa propriété bénéficiaire totale à environ 3,65 millions d'actions. Aucun titre dérivé n'a été exercé ou vendu, et aucune cession n'a été signalée.

Cet achat d'initié représente un investissement personnel d'environ 50 000 $, renforçant l'alignement de la direction avec les actionnaires. Les actions ont été obtenues par une émission primaire, indiquant un capital supplémentaire levé par la société.

VolitionRx Ltd. (VNRX) � Form 4 Meldung

Am 08.05.2025 erwarb der Präsident, CEO und Direktor Cameron John Reynolds während des registrierten Direktangebots des Unternehmens (Transaktionscode „P�) 78.125 Stammaktien zu je 0,64 $. Durch den Erwerb erhöht sich sein direkter Aktienbestand auf 2.609.847 Aktien. Reynolds kontrolliert außerdem 1.007.718 Aktien über Concord International, Inc. sowie 34.076 Aktien, die von seiner Ehefrau gehalten werden, was seine gesamte wirtschaftliche Beteiligung auf etwa 3,65 Millionen Aktien bringt. Es wurden keine Derivate ausgeübt oder verkauft und keine Veräußerungen gemeldet.

Dieser Insider-Kauf stellt eine Barinvestition von etwa 50.000 $ dar und stärkt die Übereinstimmung der Geschäftsführung mit den Aktionären. Die Aktien wurden durch eine Primärausgabe erworben, was auf eine zusätzliche Kapitalaufnahme des Unternehmens hinweist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reynolds Cameron John

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/05/2025 P 78,125(1) A $0.64 2,609,847 D
Common Stock 1,007,718 I By Concord International, Inc.(2)
Common Stock 34,076 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.
2. The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.
Remarks:
/s/ Cameron John Reynolds 08/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

66.55M
83.43M
18.4%
20.49%
0.35%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
United States
HENDERSON